Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
PERI
Xcell Therapeutics
★
Excel Therapeutics: Q1 2026 sales up but operating loss widens; R&D and market expansion continue
05/15/2026, 10:57 AM
PERI
Xcell Therapeutics
★
Xcell Therapeutics: 2025 Revenue Slightly Up but Operating Loss Widens to KRW 10.9B; Debt Ratio Soars
05/15/2026, 10:53 AM